8-K: Revvity Reports Q3 2024 Results: Revenue Growth and Increased EPS Guidance

Revvity announced positive revenue growth and raised its full-year adjusted EPS guidance in its third quarter 2024 financial results.

Summary

• Revvity reported a revenue of $684 million for the third quarter of 2024, showing a 2% increase both on a reported and organic basis compared to the same period last year.
• GAAP earnings per share (EPS) were $0.77, a significant increase from $0.08 in the prior year, while adjusted EPS from continuing operations reached $1.28, up from $1.18.
• The company's GAAP operating income from continuing operations was $98 million, compared to $69 million in the same period last year, with a margin of 14.3% versus 10.3%.
• Adjusted operating income was $193 million, up from $185 million, with an adjusted operating profit margin of 28.3%, compared to 27.5% last year.
• Revvity has updated its full-year 2024 revenue guidance to $2.75-$2.77 billion, reflecting foreign currency changes and assuming 0% to 1% organic growth.
• The company also raised its full-year adjusted EPS guidance to a range of $4.83 to $4.87.
• A new $1 billion share repurchase program was authorized, replacing the remainder of the existing program from May 2023.
• The Life Sciences segment saw a 2% decrease in reported revenue and a 3% decrease in organic revenue, while the Diagnostics segment experienced a 6% increase in reported revenue and a 5% increase in organic revenue.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the return to revenue growth, improved EPS, increased guidance, and a new share repurchase program. While there are some challenges in the Life Sciences segment, the overall tone is optimistic and forward-looking.

Positives

• The company achieved positive revenue growth in Q3 2024, reversing a previous trend.
• There was a significant increase in both GAAP and adjusted EPS compared to the same period last year.
• The company's operating profit margins improved year-over-year.
• The Diagnostics segment demonstrated strong revenue growth.
• The authorization of a new $1 billion share repurchase program indicates confidence in the company's financial position.
• The company has raised its full-year adjusted EPS guidance.

Negatives

• The Life Sciences segment experienced a decrease in both reported and organic revenue.
• The company's full-year revenue guidance was updated to reflect recent changes in foreign currency exchange rates.

Risks

• The company's performance is subject to market fluctuations and global economic conditions.
• There is a risk of not introducing new products in a timely manner.
• The company faces risks related to acquisitions and divestitures, including integration challenges.
• The company is exposed to competition and fluctuations in quarterly operating results.
• Disruptions in supply chains, IT systems, and cybercrime pose potential risks.
• The company's ability to protect intellectual property and comply with regulations is crucial.
• Economic and political risks associated with foreign operations could impact performance.
• The company's stock price is subject to significant fluctuations.

Future Outlook

The company has updated its full-year 2024 revenue guidance to $2.75-$2.77 billion and raised its adjusted EPS guidance to a range of $4.83 to $4.87. The company assumes 0% to 1% organic growth for the full year.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company performed well during the third quarter with a return to positive revenue growth, strong margins, and excellent cash flow.
• He also expressed optimism about the company's ability to make a meaningful difference around the world through innovation and partnerships.

Industry Context

Revvity's results reflect a mixed performance across its segments, with strong growth in Diagnostics offsetting a decline in Life Sciences. This is in line with the broader trends in the life sciences and diagnostics industries, where some segments are experiencing higher growth than others. The company's focus on innovation and strategic partnerships is consistent with industry best practices.

Comparison to Industry Standards

• Revvity's 2% revenue growth is moderate compared to some high-growth biotech companies, but it is a positive sign given the current economic climate.
• The adjusted EPS of $1.28 is competitive with other companies in the diagnostics and life sciences space, such as Thermo Fisher Scientific and Danaher, although direct comparisons are difficult due to different business models and accounting practices.
• The company's operating margin of 28.3% is strong and indicates efficient cost management, which is comparable to industry leaders.
• The $1 billion share repurchase program is a significant move and suggests confidence in the company's future cash flow, similar to actions taken by other large cap companies in the sector.

Stakeholder Impact

• Shareholders will benefit from the increased EPS and the share repurchase program.
• Employees may be positively impacted by the company's improved financial performance and future growth prospects.
• Customers will benefit from the company's continued innovation and focus on advancing science and healthcare.
• Suppliers and creditors will likely see a stable and reliable business partner.

Next Steps

• The company will host an Investor Day on November 21st.
• The company will continue to execute its share repurchase program.
• The company will focus on innovation and strategic partnerships to drive future growth.

Key Dates

Keywords

Revvity, Financial Results, Q3 2024, EPS, Revenue Growth, Share Repurchase, Diagnostics, Life Sciences, Guidance, Operating Income